Table 3.
Characteristic | Model 1 | Model 2 | Model 3 | Model 4 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Minimally Adjusteda | +Adjusted for GFR, Up/cb | Multivariable Adjustedc | +Mineral Metabolitesd | |||||||||
RT | 95% CI | P Value | RT | 95% CI | P Value | RT | 95% CI | P Value | RT | 95% CI | P Value | |
Plasma FGF23 tertiles, RU/ml | ||||||||||||
<100 | Reference | Reference | Reference | Reference | ||||||||
100–169 | 0.56 | 0.39 to 0.79 | 0.001 | 0.70 | 0.51 to 0.95 | 0.02 | 0.68 | 0.51 to 0.92 | 0.01 | 0.69 | 0.50 to 0.94 | 0.02 |
≥170 | 0.31 | 0.22 to 0.44 | <0.001 | 0.59 | 0.43 to 0.80 | 0.001 | 0.60 | 0.44 to 0.81 | 0.001 | 0.59 | 0.42 to 0.82 | 0.002 |
P for linear trend | <0.001 | 0.003 | 0.004 | 0.0 | ||||||||
Plasma FGF23, per doubling | 0.64 | 0.56 to 0.72 | <0.001 | 0.81 | 0.73 to 0.91 | <0.001 | 0.82 | 0.74 to 0.91 | <0.001 | 0.82 | 0.73 to 0.92 | 0.001 |
Serum 1,25(OH)2D tertile, pg/ml | ||||||||||||
>34 | Reference | Reference | Reference | Reference | ||||||||
25–34 | 0.66 | 0.45 to 0.96 | 0.03 | 0.81 | 0.59 to 1.1 | 0.18 | 0.84 | 0.61 to 1.14 | 0.26 | 0.88 | 0.65 to 1.19 | 0.41 |
<25 | 0.42 | 0.29 to 0.61 | <0.001 | 0.71 | 0.52 to 0.97 | 0.03 | 0.80 | 0.58 to 1.09 | 0.15 | 0.83 | 0.61 to 1.13 | 0.24 |
P for linear trend | <0.001 | 0.09 | 0.34 | 0.50 | ||||||||
Serum 1,25(OH)2D, per 10 pg/ml lower | 0.66 | 0.57 to 0.76 | <0.001 | 0.84 | 0.74 to 0.95 | 0.0 | 0.89 | 0.79 to 0.99 | 0.03 | 0.90 | 0.80 to 1.00 | 0.06 |
, additionally adjusted; Up/c, urine protein-to-creatinine ratio; RT, relative time; 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
Adjusted for gender, age, and race.
Additionally adjusted for GFR, Up/c.
Additionally adjusted for systolic BP z-score, glomerular diagnosis, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, active vitamin D, and phosphate binder use. This is the primary model of interest.
Additionally adjusted for mineral metabolites [phosphorus z-score, tertiles of FGF23, 25OHD, and 1,25(OH)2D] other than the primary exposure variable.